Stimulatory effect of secretin on pancreatic polypeptide in diabetic patients.

Toyota, Takayoshi; Koizumi, Masaru; Kai, Yukihiro; Miura, Masaya; Umetsu, Masanori; Suzuki, Susumu; Gotō, Yoshio

doi:10.1507/endocrj1954.27.145

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma hormone levels were assayed by specific radioimmunoassays for PP (Toyota et al 1980), glucagon (Toyota et al 1982), insulin (Toyota et al 1982), gastrin (Nakanome et al 1981), and growth hormone (Hanew et al 1980). Hormone content of the tumor was also analysed by radioimmunoassay for somatostatin (Yanaihara et al 1978), PP, vasoactive intestinal polypeptide (VIP, Yanaihara et al 1977), glucagon, /3-MSH, ACTH (Abe et al 1979), and gastrin.…”

Section: Methodsmentioning

confidence: 99%

Somatostatinoma syndrome accompanied by overproduction of pancreatic polypeptide.

Nakanome

Koizumi

Fujiya

et al. 1984

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

A case of somatostatin and pancreatic polypeptide (PP) producing tumor of the pancreas is presented. A 65-year-old woman was admitted for the evaluation of the tumor in the right upper quadrant of the abdomen. Clinical abnormalities included diabetic glucose intolerance, pancreatic insufficiency and marked dilatation of gallbladder. Marked high concentration of plasma PP and low levels of plasma insulin and glucagon were observed before operation. Plasma insulin concentrations in response to oral glucose tolerance test and arginine infusion were markedly low. A large quantity of somatostatin (4,300 ng/g ww) as well as PP (1,340 ng/g ww) was detected in the tumor, and somatostatin cells and PP cells were determined by immunofluorescence studies. After operation, pancreatic insufficiency and glucose intolerance were improved, and the patient made a favorable progress. somatostatinoma syndrome ; pancreatic polypeptide ; pancreatic endocrine tumor

show abstract